XIGDUO XR® is a product of AstraZeneca Group and has been approved in 61 countries to date including US, EU and Japan.
XIGDUO XR® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.